Korro Bio, Inc. Operating Income
Korro Bio, Inc. (KRRO) reported Operating Income of -$20.11 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-06
- Korro Bio, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$20.11M.
- Korro Bio, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$20.44M.
- Korro Bio, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$50.40M.
- Korro Bio, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$19.24M.
- Korro Bio, Inc. operating income (loss) for fiscal 2025 was -$121.86M.
- Korro Bio, Inc. operating income (loss) for fiscal 2024 was -$91.91M.
- Korro Bio, Inc. operating income (loss) for fiscal 2023 was -$84.53M.
- Korro Bio, Inc. operating income (loss) for fiscal 2022 was -$59.00M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 9 month as first filed | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$20.11M 10-Q · filed 2026-08-06 | -$40.55M 10-Q · filed 2026-08-06 | -$90.94M derived: sum of 3 quarters · filed 2026-08-06 | -$110.18M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | -$20.44M 10-Q · filed 2026-05-07 | -$70.83M derived: sum of 2 quarters · filed 2026-05-07 | -$90.07M derived: sum of 3 quarters · filed 2026-05-07 | -$117.27M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | -$50.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$69.63M derived: sum of 2 quarters · filed 2026-03-12 | -$96.83M derived: sum of 3 quarters · filed 2026-08-06 | -$121.86M 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | -$19.24M 10-Q · filed 2025-11-12 | -$46.44M derived: sum of 2 quarters · filed 2026-08-06 | -$71.46M 10-Q · filed 2025-11-12 | -$94.50M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | -$27.20M 10-Q · filed 2026-08-06 | -$52.22M 10-Q · filed 2026-08-06 | -$75.26M derived: sum of 3 quarters · filed 2026-08-06 | -$98.55M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | -$25.02M 10-Q · filed 2026-05-07 | -$48.06M derived: sum of 2 quarters · filed 2026-05-07 | -$71.35M derived: sum of 3 quarters · filed 2026-05-07 | -$95.48M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | -$23.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$46.33M derived: sum of 2 quarters · filed 2026-03-12 | -$70.46M derived: sum of 3 quarters · filed 2026-03-12 | -$91.91M 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | -$23.29M 10-Q · filed 2025-11-12 | -$47.42M derived: sum of 2 quarters · filed 2025-11-12 | -$68.87M 10-Q · filed 2025-11-12 | -$95.76M derived: sum of 4 quarters · filed 2025-11-12 | ||||
| 2024-06-30 | -$24.13M 10-Q · filed 2025-08-12 | -$45.58M 10-Q · filed 2025-08-12 | -$72.47M derived: sum of 3 quarters · filed 2025-08-12 | -$91.62M derived: sum of 4 quarters · filed 2025-08-12 | ||||
| 2024-03-31 | -$21.45M 10-Q · filed 2025-05-07 | -$48.35M derived: sum of 2 quarters · filed 2025-05-07 | -$67.49M derived: sum of 3 quarters · filed 2025-05-07 | -$85.90M derived: sum of 4 quarters · filed 2025-05-07 | ||||
| 2023-12-31 | -$26.89M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | -$46.04M derived: sum of 2 quarters · filed 2025-03-18 | -$64.45M derived: sum of 3 quarters · filed 2025-03-18 | -$84.53M 10-K · filed 2025-03-18 | ||||
| 2023-09-30 | -$19.15M 10-Q · filed 2024-11-12 | -$12.66M 10-Q · filed 2023-11-02 | -$37.56M derived: sum of 2 quarters · filed 2024-11-12 | -$57.64M 10-Q · filed 2024-11-12 | -$45.01M 10-Q · filed 2023-11-02 | -$51.83M derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-06-30 | -$18.41M 10-Q · filed 2024-08-13 | -$11.83M 10-Q · filed 2023-08-10 | -$38.49M 10-Q · filed 2024-08-13 | -$32.34M 10-Q · filed 2023-08-10 | -$32.69M derived: sum of 3 quarters · filed 2024-08-13 | -$52.96M derived: sum of 4 quarters · filed 2024-08-13 | ||
| 2023-03-31 | -$20.09M 10-Q · filed 2024-05-14 | -$20.51M 10-Q · filed 2023-05-12 | -$14.28M derived: sum of 2 quarters · filed 2024-05-14 | -$34.55M derived: sum of 3 quarters · filed 2024-05-14 | -$55.83M derived: sum of 4 quarters · filed 2024-05-14 | |||
| 2022-12-31 | $5.81M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | -$14.47M derived: sum of 2 quarters · filed 2024-03-26 | -$35.74M derived: sum of 3 quarters · filed 2024-03-26 | -$59.00M 10-K · filed 2024-03-26 | -$83.00M 10-K · filed 2023-03-10 | |||
| 2022-09-30 | -$20.27M 10-Q · filed 2023-11-02 | -$41.55M derived: sum of 2 quarters · filed 2023-11-02 | -$64.81M 10-Q · filed 2023-11-02 | -$86.17M derived: sum of 4 quarters · filed 2023-11-02 | ||||
| 2022-06-30 | -$21.27M 10-Q · filed 2023-08-10 | -$44.53M 10-Q · filed 2023-08-10 | -$65.89M derived: sum of 3 quarters · filed 2023-08-10 | -$90.88M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | -$23.26M 10-Q · filed 2023-05-12 | -$44.62M derived: sum of 2 quarters · filed 2023-05-12 | -$69.61M derived: sum of 3 quarters · filed 2023-05-12 | -$87.09M derived: sum of 4 quarters · filed 2023-05-12 | ||||
| 2021-12-31 | -$21.36M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | -$46.35M derived: sum of 2 quarters · filed 2023-03-10 | -$63.83M derived: sum of 3 quarters · filed 2023-03-10 | -$84.03M 10-K · filed 2023-03-10 | ||||
| 2021-09-30 | -$24.99M 10-Q · filed 2022-11-08 | -$42.47M derived: sum of 2 quarters · filed 2022-11-08 | -$62.67M 10-Q · filed 2022-11-08 | -$72.95M derived: sum of 4 quarters · filed 2022-11-08 | ||||
| 2021-06-30 | -$17.48M 10-Q · filed 2022-08-09 | -$37.68M 10-Q · filed 2022-08-09 | -$47.96M derived: sum of 3 quarters · filed 2022-08-09 | -$53.38M derived: sum of 4 quarters · filed 2022-08-09 | ||||
| 2021-03-31 | -$20.20M 10-Q · filed 2022-05-04 | -$30.48M derived: sum of 2 quarters · filed 2022-05-04 | -$35.89M derived: sum of 3 quarters · filed 2022-05-04 | -$42.09M derived: sum of 4 quarters · filed 2022-05-04 | ||||
| 2020-12-31 | -$10.28M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$15.70M derived: sum of 2 quarters · filed 2022-03-15 | -$21.89M derived: sum of 3 quarters · filed 2022-03-15 | -$27.55M 10-K · filed 2022-03-15 | ||||
| 2020-09-30 | -$5.42M 10-Q · filed 2021-11-15 | -$11.62M derived: sum of 2 quarters · filed 2021-11-15 | -$17.27M 10-Q · filed 2021-11-15 | -$23.76M derived: sum of 4 quarters · filed 2021-11-15 | ||||
| 2020-06-30 | -$6.20M 10-Q · filed 2021-08-12 | -$11.86M 10-Q · filed 2021-08-12 | -$18.34M derived: sum of 3 quarters · filed 2021-08-12 | -$19.59M derived: sum of 4 quarters · filed 2021-08-12 | ||||
| 2020-03-31 | -$5.66M 10-Q · filed 2021-05-13 | -$12.14M derived: sum of 2 quarters · filed 2021-05-13 | -$13.39M derived: sum of 3 quarters · filed 2021-05-13 | -$20.41M derived: sum of 4 quarters · filed 2021-05-13 | ||||
| 2019-12-31 | -$6.49M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | -$7.74M derived: sum of 2 quarters · filed 2021-03-29 | -$14.76M derived: sum of 3 quarters · filed 2021-03-29 | -$20.68M 10-K · filed 2021-03-29 | ||||
| 2019-09-30 | -$1.25M 10-Q · filed 2020-11-16 | -$8.27M derived: sum of 2 quarters · filed 2020-11-16 | -$14.19M 10-Q · filed 2020-11-16 | -$19.51M derived: sum of 4 quarters · filed 2020-11-16 | ||||
| 2019-06-30 | -$7.02M 10-Q · filed 2020-08-12 | -$12.94M 10-Q · filed 2020-08-12 | -$18.26M derived: sum of 3 quarters · filed 2020-08-12 | -$23.32M derived: sum of 4 quarters · filed 2020-08-12 | ||||
| 2019-03-31 | -$5.92M 10-Q · filed 2020-05-14 | -$11.24M derived: sum of 2 quarters · filed 2020-05-14 | -$16.30M derived: sum of 3 quarters · filed 2020-05-14 | |||||
| 2018-12-31 | -$5.33M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | -$10.38M derived: sum of 2 quarters · filed 2020-03-26 | -$18.94M 10-K · filed 2020-03-26 | |||||
| 2018-09-30 | -$5.06M 10-Q · filed 2019-11-18 | -$13.62M 10-Q · filed 2019-11-18 | ||||||
| 2017-12-31 | -$16.31M 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |